Commercializing Cell and Gene Therapies

By Xcenda

Clinically promising, commercially challenging. Discover the go-to-market strategies to succeed when the patient is in the supply chain.
Topics:
Cell and gene therapy Commercialization

Related Content

Emerging Gene Therapies for Hemophilia in the United States—Value Drivers in a Crystal Ball

Xcenda
May 2020

Tumor-Agnostic Therapy Assessment: Following Regulatory Approval, What Challenges Exist for HTAs?

Xcenda
August 2019

Manufacturers

What manufacturers need to know about reimbursement and patient support for cell and gene therapies

Ana Stojanovska; Myra Reinhardt
July 2021